Business Description
MorphoSys AG
ISIN : DE0006632003
Share Class Description:
XTER:MOR: Ordinary SharesDescription
MorphoSys AG is a biopharmaceutical company dedicated to the discovery, development and commercialization of therapies for people living with cancer and autoimmune diseases. MorphoSys is advancing its own pipeline of new drug candidates and has created antibodies that are developed by partners in different areas of unmet medical need. Tremfya (guselkumab) - developed by Janssen Research & Development, LLC and marketed by Janssen Biotech, Inc. for the treatment of plaque psoriasis - became the first drug based on MorphoSys antibody technology to receive regulatory approval. The U.S. Food and Drug Administration granted accelerated approval of the company's proprietary product Monjuvi (tafasitamab-cxix) in combination with lenalidomide for patients with a certain type of lymphoma.
Financial Strength
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 1.07 | |||||
| Equity-to-Asset | 0.02 | |||||
| Debt-to-Equity | 12.97 | |||||
| Debt-to-EBITDA | -12.44 | |||||
| Altman Z-Score | 0.42 | |||||
| Beneish M-Score | -3.19 | |||||
| WACC vs ROIC | ||||||
Growth Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -11.1 | |||||
| 3-Year FCF Growth Rate | -173.8 | |||||
| 3-Year Book Growth Rate | -59 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 41.15 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 23.9 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 11.85 | |||||
| 9-Day RSI | 26.4 | |||||
| 14-Day RSI | 37.71 | |||||
| 6-1 Month Momentum % | 17.77 | |||||
| 12-1 Month Momentum % | 141.69 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 3.08 | |||||
| Quick Ratio | 2.84 | |||||
| Cash Ratio | 2.58 | |||||
| Days Inventory | 301.86 | |||||
| Days Sales Outstanding | 98.58 | |||||
| Days Payable | 524.66 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -4.7 | |||||
| Shareholder Yield % | 2.11 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 75.48 | |||||
| Operating Margin % | -105.22 | |||||
| Net Margin % | -79.6 | |||||
| FCF Margin % | -82.95 | |||||
| ROE % | -226.44 | |||||
| ROA % | -8.63 | |||||
| ROIC % | -17.83 | |||||
| 3-Year ROIIC % | -39.97 | |||||
| ROC (Joel Greenblatt) % | -139.64 | |||||
| ROCE % | -2.94 | |||||
| Years of Profitability over Past 10-Year | 2 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 9.68 | |||||
| PB Ratio | 51.57 | |||||
| EV-to-EBIT | -43.71 | |||||
| EV-to-EBITDA | -48.63 | |||||
| EV-to-Revenue | 10.43 | |||||
| EV-to-FCF | -12.57 | |||||
| Price-to-Median-PS-Value | 0.47 | |||||
| Earnings Yield (Greenblatt) % | -2.29 | |||||
| FCF Yield % | -7.81 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
MorphoSys AG Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 238.361 | ||
| EPS (TTM) (€) | -5.52 | ||
| Beta | 0 | ||
| Volatility % | 78.7 | ||
| 14-Day RSI | 37.71 | ||
| 14-Day ATR (€) | 0.302161 | ||
| 20-Day SMA (€) | 67.72 | ||
| 12-1 Month Momentum % | 141.69 | ||
| 52-Week Range (€) | 14.52 - 69.75 | ||
| Shares Outstanding (Mil) | 37.66 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 0 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
MorphoSys AG Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
MorphoSys AG Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
MorphoSys AG Frequently Asked Questions
What is MorphoSys AG(XTER:MOR)'s stock price today?
The current price of XTER:MOR is €67.25. The 52 week high of XTER:MOR is €69.75 and 52 week low is €14.52.
When is next earnings date of MorphoSys AG(XTER:MOR)?
The next earnings date of MorphoSys AG(XTER:MOR) is 2025-03-13 Est..
Does MorphoSys AG(XTER:MOR) pay dividends? If so, how much?
MorphoSys AG(XTER:MOR) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers